We have been developing prodrugs of anticancer agents such as 5-fluorouracil (5-FU) that are activated by irradiation under hypoxic conditions via one-electron reduction. Among them, OFU001 \[\text{1-}(2'\text{-oxopropyl})-5\text{-fluorouracil}\] is a prototype radiation-activated prodrug. In this study, we investigated the radiation chemical reactivity and the biological effects of OFU001. This prodrug is presumed to release 5-FU through incorporation of hydrated electrons into the antibonding \(\sigma^*\) orbital of the \(\text{C}(1')-\text{N}(1)\) bond. Hydrated electrons are active species derived from radiolysis of water, but are readily deactivated by \(O_2\) into superoxide anion radicals (\(O_2^-\)) under conditions of aerobic irradiation. Therefore, 5-FU release occurs highly specifically upon irradiation under hypoxic conditions. OFU001 dissolved in phosphate buffer released 5-FU with a \(G\)-value (mol number of molecules that are decomposed or produced by 1 J of absorbed radiation energy) of \(1.9 \times 10^{-7}\) mol/J following hypoxic irradiation, while the \(G\)-value for 5-FU release was \(1.0 \times 10^{-4}\) mol/J following aerobic irradiation. However, the \(G\)-values for decomposition of OFU001 were almost the same, i.e., \(3.4 \times 10^{-7}\) mol/J following hypoxic irradiation and \(2.5 \times 10^{-7}\) mol/J following aerobic irradiation. When hypoxically irradiated (7.5–30 Gy) OFU001 was added to murine SCCVII cells for 1–24 h, a significant cell-killing effect was observed. The degree of this cytotoxicity was consistent with that of authentic 5-FU at the corresponding concentrations. On the other hand, cytotoxicity was minimal when the cells were treated with aerobically irradiated or unirradiated OFU001. This compound had no radiosensitizing effect against SCCVII cells under either aerobic or hypoxic conditions when the drug was removed immediately after irradiation. Since hypoxia is generally most marked in tumors and irradiation is applied at the tumor site, this concept of prodrug design appears to be potentially useful for selective tumor treatment with minimal adverse effects of anticancer agents.

Key words: Prodrug — Radiation-activated — 5-Fluorouracil — Radiation — Hypoxia
structure. The proposed mechanism of 5-FU release by irradiation is shown in Fig. 1. Hydrated electrons \(e^{-aq}\) are thought to be incorporated into the compound to form the corresponding \(\pi^*\) anion radical, which is thermally activated to the \(\sigma^*\) anion radical with a weakened C(1')-N(1) bond. Subsequently, hydrolytic dissociation of the C(1')-N(1) bond occurs, releasing 5-FU. In this study, we investigated the radiation chemical reactivity and the in vitro antitumor effect of OFU001.

MATERIALS AND METHODS

**Compound** This compound has been reported by a Korean group\(^{10}\) as one of a series of acyclic 5-substituted pyrimidine nucleoside analogues. For this study, we synthesized OFU001 by reaction of 2,4-bis(trimethylsilyloxy)-5-fluoropyrimidine (1.21 g) and bromoacetone (5.0 ml) in acetonitrile under an N\(_2\) atmosphere. After 1 h of refluxing, 1.0 ml of methanol was added to the reaction mixture, and the mixture was stirred for 30 min at room temperature. The product was separated and purified by silica gel column chromatography (yield 53%) and identified by nuclear magnetic resonance and high-resolution mass spectroscopy. OFU001 has a molecular weight of 186. The partition coefficient in octanol/water measured by a published method\(^{11}\) was 0.067. As a reference compound, 5-FU obtained from Tokyo Kasei Organic Chemicals (Tokyo) was also used.

**Radiation chemistry** To measure radiolytic decomposition of OFU001 and release of 5-FU, OFU001 dissolved in phosphate buffer (pH 7.0) was irradiated with an X-ray apparatus (250 kVp, 15 mA, 1.0 mm Al filter) at a dose rate of 5 Gy/min under aerobic or hypoxic conditions at room temperature. To establish hypoxia, Ar gas was bubbled for 15 min according to a published method\(^{11}\) and the test tubes were then sealed. Immediately thereafter, the solution was subjected to high-performance liquid chromatography (HPLC) analysis. HPLC was performed using a NANOSPACE SI-1 (Shiseido, Tokyo) equipped with a UG120 C18 semimicro-column (1.5 mm\(\Phi\)×250 mm), and the elution peaks were detected using a UV-VIS detector 2002 at 264 nm wavelength. Phosphate buffer containing 1% methanol (pH 3) was used as an eluent.

**In vitro effects** Exponentially growing murine SCCVII cells with a doubling time of 14 h were used. The cells were cultured in Eagle’s minimum essential medium (MEM) containing 12.5% fetal bovine serum. In all experiments, colonies containing 50 or more cells were counted after fixation on day 7 following drug treatment. The control plating efficiency of this cell line was 63±7 (SD)% during the experiments. To investigate the cytotoxicity of irradiated and unirradiated OFU001, 250 SCCVII cells were plated onto each culture dish 7.5 h before treatment with the drugs. MEM containing 1 mM OFU001 was irradiated with 7.5–30 Gy under aerobic or hypoxic conditions. To make the drug-containing medium hypoxic, it was bubbled with 95% N\(_2\)/5% CO\(_2\) gas for 15 min and then the flask was sealed. After irradiation with 4 MV X rays at a dose rate of 5 Gy/min, the drug-containing MEM was supplemented with fetal bovine serum at 10%, and then the medium in the dishes containing SCCVII cells was replaced with drug-containing medium. After 1, 3, 6, 12, or 24 h, the drug-containing medium was discarded, and the cultures were washed once with phosphate-buffered saline, and supplemented with fresh medium. For controls, MEM containing no drug was also bubbled with the gas, irradiated, and added to control cell cultures; bubbling and irradiation of MEM did not change the plating efficiency of SCCVII cells. Also, one group of cell cultures was treated with unirradiated OFU001 after bubbling with the gas.

The cytotoxicity of 5-FU was also investigated using SCCVII cells. As in the experiment with OFU001, exponentially growing 250 SCCVII cells were plated onto dishes. After 7.5 h, the medium was replaced with MEM containing 2.5, 5, or 10 \(\mu\)M 5-FU and 10% serum, and 1, 3, 6, 12, or 24 h later, the drug-containing medium was removed, then the cultures were washed once, and replenished with fresh MEM.

Since OFU001 possesses electron-capturing capacity, the electron-affinic radiosensitizing activity of OFU001 was also investigated. Following published methods,\(^{13}\) SCCVII cells were treated with 1 mM OFU001 in sealed test tubes 40 min prior to and during irradiation under hypoxic conditions. The concentration of 1 mM has been most often used to test radiosensitizers in our laboratory.\(^{11,\;13}\) Immediately after irradiation with 4 MV X rays, the drug was removed by centrifugation and the cells were replated. To investigate aerobic radiosensitization, SCCVII cells plated 7.5 h beforehand were treated in dishes with 1 mM OFU001 40 min prior to and during

Fig. 1. Proposed mechanism for conversion of OFU001 into 5-FU. e\(^{-aq}\) hydrated electron. See text for detailed explanation.
Radiation-activated Prodrug of 5-FU

irradiation. After irradiation, the drug-containing medium was removed, and the cultures were washed, and replenished with fresh medium.

RESULTS

Radiation chemistry  Fig. 2 shows dose-response curves for the decomposition of OFU001 and the release of 5-FU upon irradiation of a solution of 0.1 mM OFU001 in phosphate buffer under aerobic or hypoxic conditions. Both reactions were radiation-dose dependent, and the dose-response curves could be fitted with straight lines by linear regression (all \( r > 0.988, P < 0.05 \)). While the decomposition of OFU001 was slightly more efficient with hypoxic radiolysis than with aerobic radiolysis, the release of 5-FU was greatly enhanced under hypoxic conditions. The \( G \)-value (mol number of molecules that are decomposed or produced by 1 J of absorbed radiation energy) for decomposition of OFU001 was 3.4 (95% confidence interval, CI, 3.1 to 3.8) \( \times 10^{-7} \) mol/J under hypoxic conditions and 2.5 (CI, 2.1 to 2.9) \( \times 10^{-7} \) mol/J under aerobic conditions, while the \( G \)-values for release of 5-FU were 1.9 (CI, 1.8 to 2.0) \( \times 10^{-7} \) mol/J and 1.0 (CI, 0.95 to 1.04) \( \times 10^{-8} \) mol/J, respectively. Thus, 55% of decomposed OFU001 was converted to 5-FU upon irradiation under hypoxic conditions. The release of 5-FU from OFU001 (0.1 mM) in MEM occurred with the same efficiency as in the phosphate buffer, with a \( G \)-value for 5-FU release of 1.9 (CI, 1.7 to 2.2) \( \times 10^{-7} \) mol/J. The release of 5-FU was substantially identical (\( G \)-value: 1.9 [CI, 1.8 to 2.0] \( \times 10^{-7} \) mol/J) even when the concentration of OFU001 was increased to 1 mM.

The metabolites of OFU001 other than 5-FU produced by aerobic and hypoxic irradiation are now under investigation. Following aerobic irradiation, there were three major peaks on the HPLC chart. One of them has been

![Fig. 2. Decomposition of OFU001 (A) and release of 5-FU (B) in phosphate buffer after aerobic (○) or hypoxic (●) irradiation.](image)

![Fig. 3. Cytotoxic effect of OFU001 against SCCVII cells. A, OFU001-containing medium was sham-irradiated (△), aerobically irradiated with 30 Gy (○) or hypoxically irradiated at 30 Gy (●), and then added to SCCVII cells. B, OFU001-containing medium was irradiated under hypoxic conditions with lower doses. ● 7.5 Gy, ▲ 15 Gy, ■ 22.5 Gy. Error bars represent SE of 3–4 experiments.](image)
shown to represent 1-(2′-oxopropyl)-5-hydroxyuracil, and the identity of the other two major metabolites is now being determined (data to be published). Following hypoxic irradiation, however, there were no major peaks other than those for OFU001 and 5-FU on the HPLC chart.

**In vitro effects**

Fig. 3 compares the cytotoxic effects of irradiated and unirradiated OFU001. OFU001 aerobically irradiated with 30 Gy or unirradiated OFU001 showed minimal cytotoxicity, and after 24 h of contact with them, only 15–19% of SCCVII cells were killed. On the other hand, OFU001 hypoxically irradiated with 30 Gy showed much higher cytotoxicity; the cell survival was 29% (95% CI, 24 to 39%) after 24 h of contact. This cytotoxic effect was clearly dependent on the drug contact time and the radiation dose.

Fig. 4 shows the cytotoxic effect of 5-FU on SCCVII cells. The effect was dependent on the concentration and contact time. The effects of 5-FU at 2.5 and 5 µM were nearly equivalent to those of OFU001 irradiated hypoxically with 15 and 30 Gy, respectively. From Fig. 2, the concentration of 5-FU released from OFU001 is estimated to be 2.8 µM at 15 Gy of hypoxic irradiation and 5.5 µM at 30 Gy. Since 10% serum was added to the medium containing OFU001 after irradiation, the final concentration of 5-FU in the medium should be approximately 2.5 µM after 15 Gy and 5 µM after 30 Gy. Thus, the cytotoxic effects of hypoxically irradiated OFU001 agreed well with those of 5-FU at the corresponding concentrations.

Fig. 5 shows the absence of a radiosensitizing effect of OFU001. When OFU001 was removed immediately after irradiation, the compound (1 mM) had no effect under either aerobic or hypoxic conditions.

**DISCUSSION**

Among various types of antitumor prodrugs, OFU001, which is activated by hypoxic irradiation, clearly represents a novel class. Regarding the mechanism of activation shown in Fig. 1, attempts are being made in our laboratory to confirm the formation of the anion radical intermediates using pulse radiolysis. In this regard, Mori et al. have detected the transient absorption of carbonyl π∗ anion radicals following hypoxic irradiation of the N(1)-C(5) linked 5-FU dimer in solution in phosphate buffer. The incorporation of the radiochemically generated hydrated electron into the carbonyl group of electron-affinic compounds was previously reported by Adams and Dewey. The contribution of the σ∗ anion radical that is in resonance with the π∗ anion radical to the reductive dissociation of the C-Cl bond has been discussed by Santiago et al. Therefore, the reaction process shown in Fig. 1 is a combination of two reactions that were previously reported independently. Hydrated electrons are abundantly produced during hypoxic irradiation, but upon aerobic irradiation, the hydrated electrons are captured by electron-affinic oxygen to form reactive superoxide anion radicals (O2−). Therefore, this type of activation of OFU001 is essentially specific to irradiation under hypoxic conditions. The 2-oxo structure of the side chains at the N(1)-position of 5-FU
has been proven to play a crucial role in the release of 5-FU. In contrast to OFU001, an analogue of OFU001 bearing a 1-propyl substituent without the 2-oxo function released no 5-FU upon irradiation under hypoxic conditions. Recently, Wilson et al. reported prodrugs of mechlorethamine which are activated by metabolic or radiolytic nitroreduction under hypoxic conditions. Those compounds are also hypoxia-specific, but their mechanism of activation is different from that of our compound.

Among many prodrugs that we have investigated, OFU001 possesses the simplest side chain and has one of the highest efficiencies of releasing 5-FU. The G-value of 1.9×10⁻³ mol/J for 5-FU release was much higher than that of the previously reported 5-FU dimer (7.5×10⁻⁴ mol/J). Therefore, we investigated the efficacy of OFU001 in more detail. It exhibited good characteristics as a prodrug in in vitro experiments. OFU001 itself had very low cytotoxicity against SCCVII cells. In phosphate buffer, OFU001 was converted 19 times more efficiently into 5-FU following hypoxic than aerobic irradiation. This G-value ratio (hypoxia to air) was much higher than that of the 2.4 for the 5-FU dimer. In accord with the radiation chemical reactivity, OFU001 had very low cytotoxicity when irradiated aerobically, but it showed definite effects when irradiated hypoxically. The cytotoxic effects of a given concentration of hypoxically irradiated OFU001 against SCCVII cells were similar to those of 5-FU at a concentration equivalent to that released by the OFU001. This observation suggests that the other byproducts derived from radioysis of OFU001 are not cytotoxic.

This process of radiation activation is expected to work also in vivo, and we have started in vivo evaluation of this compound. In a preliminary study, we have observed release of 5-FU in in vivo tumors following intraperitoneal injection of OFU001 and irradiation of air-breathing mice. The amount of 5-FU release was similar to that expected from the in vitro experiments (Shibamoto et al., data to be published). When 5 µM 5-FU is released within hypoxic tumor cells, some degree of in vivo effect may be expected, judging from the clinically achievable 5-FU concentrations in tumors and the effect of 5-FU at those dosages. To obtain this concentration of 5-FU, however, radiation doses of 25–30 Gy are necessary. These doses are used in clinics for intraoperative radiotherapy and radiosurgery, which are rapidly being introduced worldwide. So, OFU001 may be useful in clinics when combined with these treatment modalities, but more efficient compounds would be more suitable for clinical application.

We have therefore surveyed many other compounds having various 2-oxo side chains at the N(1)-position of 5-FU. Some compounds showed slightly, but not greatly, higher efficiency of release of 5-FU than OFU001, and at present it seems difficult to develop prodrugs of 5-FU which are more suitable for clinical application using this idea. However, we have confirmed that the concept of hypoxic radiation activation is applicable to other antitumor and cytotoxic agents (Nishimoto et al., unpublished data). The 2-oxo side-chain structure seems to be important for developing radiation-activated prodrugs of other anticancer agents, as well. We have already synthesized several prodrugs of 5-fluoro-2'-deoxyuridine (FdUrd) having this type of side chain at their N(3)-position and are now investigating these compounds. FdUrd is one order of magnitude more efficient than 5-FU, in terms of the IC₅₀ (molar concentration causing 50% growth inhibition) values in most cell lines. Thus, FdUrd-releasing prodrugs are expected to work better than 5-FU-releasing prodrugs, including OFU001. Furthermore, we are investigating various other anticancer drugs, such as mitomycin C, that are more efficient on a molar concentration basis than 5-FU and FdUrd and are capable of carrying 2-oxoalkyl side chains.

ACKNOWLEDGMENTS

This work was supported in part by Grants-in-Aid for Scientific Research (07455339, 11877152, 10557087) from the Japanese Ministry of Education, Science, Sprots and Culture.

(Received November 26, 1999/Revised January 18, 2000/ Accepted January 21, 2000)

REFERENCES

1) Denmeade, S. R., Nagy, A., Gao, J., Lilja, H., Schally, A. V. and Isaacs, J. T. Enzymatic activation of a doxorubicin-peptide prodrug by phosphate-specific antigen. Cancer Res., 58, 2537–2540 (1998).
2) Bosslet, K., Straub, R., Blumrich, M., Czech, J., Gerken, M., Sperker, B., Kroemer, H. K., Gesson, J. P., Koch, M. and Monneret, C. Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res., 58, 1195–1201 (1998).
3) Brain, E. G., Yu, L. J., Gustafsson, K., Drewes, P. and Waxman, D. J. Modulation of P450-dependent ifosfamide pharmacokinetics: a better understanding of drug activation in vivo. Br. J. Cancer, 77, 1768–1776 (1998).
4) Kinsella, T. J., Kunugi, K. A., Vielhuber, K. A., Potter, D. M., Frittsimmons, M. E. and Collins, J. M. Preclinical evaluation of 5-iodo-2-pyrimidinone-2'-deoxyribose as a prodrug for 5-iodo-2'-deoxyuridine-mediated radiosensitization in mouse and human tissues. Clin. Cancer Res., 4, 99–109 (1998).
5) Lawrence, T. S., Rehemtulla, A., Ng, E. Y., Wilson, M., et al. Brain, E. G., Yu, L. J., Gustafsson, K., Drewes, P. and Waxman, D. J. Modulation of P450-dependent ifosfamide pharmacokinetics: a better understanding of drug activation in vivo. Br. J. Cancer, 77, 1768–1776 (1998).
4) Kinsella, T. J., Kunugi, K. A., Vielhuber, K. A., Potter, D. M., Frittsimmons, M. E. and Collins, J. M. Preclinical evaluation of 5-iodo-2-pyrimidinone-2'-deoxyribose as a prodrug for 5-iodo-2'-deoxyuridine-mediated radiosensitization in mouse and human tissues. Clin. Cancer Res., 4, 99–109 (1998).
5) Lawrence, T. S., Rehemtulla, A., Ng, E. Y., Wilson, M., et al. Brain, E. G., Yu, L. J., Gustafsson, K., Drewes, P. and Waxman, D. J. Modulation of P450-dependent ifosfamide pharmacokinetics: a better understanding of drug activation in vivo. Br. J. Cancer, 77, 1768–1776 (1998).
Trosko, J. E. and Stetson, P. L. Preferential cytotoxicity of cells transduced with cytosine deaminase compared to bystander cells after treatment with 5-fluorocytosine. Cancer Res., 58, 2588–2593 (1998).

6) Mizuno, M., Yoshida, J., Colosi, P. and Kurtzman, G. Adeno-associated virus vector containing the herpes simplex virus thymidine kinase gene causes complete regression of intracerebrally implanted human gliomas in mice, in conjunction with ganciclovir administration. Jpn. J. Cancer Res., 89, 76–80 (1998).

7) Matsukura, N., Hoshino, A., Igarashi, T., Hasegawa, H., Okino, T., Onda, M., Iijima, O., Akiyama, K., Goto, T., Takubo, K., Suzuki, S. and Shimada, T. In situ gene transfer and suicide gene therapy of gastric cancer induced by N-ethyl-N’-nitro-N-nitrosoguanidine in dogs. Jpn. J. Cancer Res., 90, 1039–1049 (1999).

8) Nishimoto, S., Hatta, H., Ueshima, H. and Kagiya, T. 1-(5′-Fluoro-6′-hydroxy-5′,6′-dihydrouracil-5′-yl)-5-fluorouracil, a novel N(1)-C(5)-linked dimer that releases 5-fluorouracil by radiation activation under hypoxic conditions. J. Med. Chem., 35, 2711–2712 (1992).

9) Mori, M., Hatta, H. and Nishimoto, S. Synthesis and structure-activity relationship of radiation activating prodrugs that release 5-fluorouracil. Proceedings of the 41st Symposium on Radiation Chemistry, Kobe, Japan, 81–82 (1998).

10) Kim, J. C., Dong, E. S., Kim, J. A., Kim, S. H., Park, J. I. and Kim, S. H. Synthesis and antitumor evaluation of acyclic 5-substituted pyrimidine nucleoside analogues. Korean J. Med. Chem., 4, 111–118 (1994).

11) Shibamoto, Y., Nishimoto, S., Shimokawa, K., Hisanaga, Y., Zhou, L., Wang, J., Sasai, K., Takahashi, M., Abe, M. and Kagiya, T. Characteristics of fluorinated nitroazole as hypoxic cell radiosensitizers. Int. J. Radiat. Oncol. Biol. Phys., 16, 1045–1048 (1989).

12) Nishimoto, S., Ide, H., Wada, T. and Kagiya, T. Radiation-induced hydroxylation of thymine promoted by electron-affinic compounds. Int. J. Radiat. Biol., 44, 585–600 (1983).

13) Shibamoto, Y., Nishimoto, S., Mi, F., Sasai, K., Kagiya, T. and Abe, M. Evaluation of various types of new hypoxic cell sensitizers using the EMTo single cell-spheroid-solid tumour system. Int. J. Radiat. Biol., 52, 347–357 (1987).

14) Mori, M., Hatta, H., Teshima, S., Numao, Y., Fujita, S., Nishimoto, S. and Takeuchi, K. N(1)-C(5)-linked 5-fluorouracil dimer that releases 5-fluorouracil by one-electron reduction: radiation- and photo-activation mechanisms. Abstracts of Papers, Part 2, 1995 International Chemical Congress of Pacific Basin Society, Honolulu, Hawaii, 657 (1995).

15) Adams, G. E. and Dewey, D. L. Hydrated electrons and radiobiological sensitization. Biochem. Biophys. Res. Commun., 12, 473–477 (1963).

16) Santiago, A. N., Takeuchi, K., Ohga, Y., Nishida, M. and Rossi, R. A. The reactivity of 1-chloro-3,3-dimethylbicyclo[2.2.2]octan-2-one in the radical mechanism of nucleophilic substitution. J. Org. Chem., 56, 1581–1584 (1991).

17) Wilson, W. R., Ferry, D. M., Tercel, M., Anderson, R. F. and Denny, W. A. Reduction of nitroaryl methyl quaternary ammonium prodrugs of mechlorethamine by radiation. Radiat. Res., 149, 237–245 (1998).

18) Peters, G. J., Lankelma, J., Kok, R. M., Noordhuis, P., van Groeningen, C. J., van der Wilt, C. L., Meyer, S. and Pinedo, H. M. Prolonged retention of high concentration of 5-fluorouracil in human and murine tumors as compared with plasma. Cancer Chemother. Pharmacol., 31, 269–276 (1993).

19) Ho, D. H., Pazdur, R., Covington, W., Brown, N., Huo, Y. Y., Lassere, Y. and Kuritani, J. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2′-tetrahydrofuryl)-5-fluorouracil. Clin. Cancer Res., 4, 2085–2088 (1998).

20) van Laar, J. A. M., Rustum, Y. M., Ackland, S. P., van Groeningen, C. J. and Peters, G. J. Comparison of 5-fluoro-2′-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer. Eur. J. Cancer, 34, 296–306 (1998).